Biocryst Pharmaceuticals (BCRX) Short term Debt (2017 - 2026)

Biocryst Pharmaceuticals has reported Short term Debt for 8 years, with the latest figure at $40.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 17.53% year-over-year to $40.3 million; the trailing twelve-month figure through Mar 2026 stood at $40.3 million (up 17.53% YoY), and the FY2025 full-year result was $38.5 million, up 17.69% from the prior year.
• Short term Debt for Q1 2026 stood at $40.3 million, up from $38.5 million in the prior quarter.
• The five-year high for Short term Debt was $40.3 million in Q1 2026, with the low at $23.6 million in Q4 2023.
• Historically, Short term Debt has averaged $33.1 million across 4 years, with a median of $33.7 million in 2024.
• Annual changes were most pronounced in 2024 — Short term Debt soared 38.66% — and 2025, when it grew 14.2%.
• Biocryst Pharmaceuticals' Short term Debt stood at $23.6 million in 2023, then soared by 38.66% to $32.7 million in 2024, then rose by 17.69% to $38.5 million in 2025, then climbed by 4.84% to $40.3 million in 2026.
• The last three Short term Debt figures came in at $40.3 million (Q1 2026), $38.5 million (Q4 2025), and $37.7 million (Q3 2025), per Business Quant data.